Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

REP 2165-Mg: Phase IIb started

October 12, 2015 7:00 AM UTC

Replicor began the open-label, Moldovan Phase IIb REP 401 trial of REP 2139-Mg or REP 2165-Mg in about 60 Caucasian patients who have received Viread tenofovir disoproxil fumarate for 24 weeks. All ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article